GCP Inspectors Need to be Highly Qualified, Says EMA

The European Commission (EC) released an  opinion article last week highlighting its expectations on the minimum standards of qualification of GCP inspectors, in particular regarding their education and training. Per the EC, an inspector must have university level education in medicine, pharmacy, pharmacology, toxicology or other fields relevant to Good Clinical Practice principles. In addition, the inspector … Read more

Different FDA Divisions Follow Different Review Times: Who Knew!

Sponsors have often complained that some divisions at FDA are inherently slower in responding than others. This trend permeates not only the review times for market approval applications but also to clinical trial applications and comment requests. In an article published in Nature Drug Discovery, senior officials at FDA acknowledged that different divisions do have different review … Read more

There is No Viable Alternative to Animal Studies

Since the onset of formal safety and efficacy testing of drugs before their market approval almost 60 yr ago, animal studies have formed the backbone of testing before a given experimental drug can be tested in humans. Supported by principles of ethical clinical research and sound scientific basis, regulators framed laws defining the kind of … Read more

Office of Generic Drugs Opens The Door a Bit to Get Timely ANDA Updates

FDA released  a new internal policy on 17th Aug whereby sponsors of ANDA applications will soon start receiving timely updates regarding the status of their application’s review. Under this new policy the Regulatory Project Managers (RPMs) at Office of Generic Drugs (OGD) will respond to any status inquiries from authorized representatives of the companies within 2 … Read more

Female Viagra Marketing Set to Test Off-Label Sale Rules Post FDA Approval

On 18th August FDA finally approved Addyi (flibanserin) popularly known as the “Female Viagra”. Third time was the charm for the manufacturer, Sprout Pharma, who learnt from there previous two failures and gamed the Advisory Committee using aggressive campaign to claim that their product should be approved despite all the safety concerns and marginal effectiveness because there was … Read more

The Promise of Bacteriophage Therapy Rekindled but Hurdles Remain

Antibiotic resistance is a mounting public health concern with the  CDC estimating the annual added cost of treating antibiotic-resistant infections at $20 billion in the US alone. The CDC also estimates that 50-70% of hospital-acquired infections are now resistant to first-line antibiotics. Given the dearth of new classes of antibiotics, drug companies are looking at non-traditional approaches … Read more

GMP Issues for 3D Printed Pills Resolved But Is It Really a Big Deal?

On 31st July 2015, FDA approved the World’s first 3D printed pill and it was widely celebrated as a major milestone and, in my ways it is, but for the reasons one may think. The approval is for a new formulation of a well-established epilepsy drug, levetiracetam, called Spritam®. With more than 80 generic drugs containing levetiracetam in … Read more